Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Do ASA and NSAIDs reduce the risk of colorectal cancer?

Sally Murray
CMAJ November 08, 2005 173 (10) 1159-1160; DOI: https://doi.org/10.1503/cmaj.051335
Sally Murray
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294(8):914-23.

Background: Regular use of ASA in patients with a history of colorectal adenoma or cancer has been shown to reduce the risk of recurrent adenoma within 1–3 years.1 Although 2 trials looking at the effect of ASA on colorectal cancer did not show a benefit after 5–10 years,2,3 it is unknown whether ASA taken for a longer duration, or at a different dose, would reduce the risk of colorectal cancer. It is also unclear whether other NSAIDs would have similar protective effects.

Design: A prospective study involving 82 911 women enrolled in the Nurses' Health Study collected data from questionnaires biennially on ASA and other NSAID use and new cases of colorectal cancer from 1980 to June 2000. From the data collected, the mean ASA intake was calculated, and women were divided into groups of regular ASA users (2 or more 325-mg tablets per week) and nonregular users. Rates of colorectal cancer were calculated for each group by dividing the number of new cases of cancer by the number of person-years of ASA use. The investigators also collected data about gastrointestinal bleeding in participants.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

Results: A total of 962 cases of colorectal cancer were found among the women during the 20 years of follow-up. Regular users of ASA had a lower risk of colorectal cancer than nonregular users. The reduced risk started after 10 years of regular use, and larger doses of ASA resulted in larger reductions in risk (Table 1, Table 2). Women who used more than 14 tablets of ASA per week for longer than 10 years had a 53% lower risk of colorectal cancer than those who did not use ASA (age-adjusted relative risk [RR] 0.47). A similar protective dose–response relation was found for NSAIDs: women who used NSAIDs regularly (2 or more tablets per week) had a 21% lower risk of colorectal cancer than nonregular users (adjusted RR 0.71, 95% confidence interval 0.64–0.97).

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2.

ASA and NSAID use were not related to reduced number of rectal cancers, and lower doses of ASA (50 mg/d) did not lower the risk of colon cancer.

The incidence of major gastointestinal bleeding events related to ASA use was also dose-related: it varied from 7.7 cases per 10 000 women who did not use ASA to 15.7 per 10 000 women taking 14 or more tablets of ASA per week. For NSAID users, the rate of gastrointestinal bleeds was 19.1 per 10 000 women taking 14 NSAID tablets per week, compared with 10.1 per 10 000 non-NSAID users.

Commentary: The study builds on previous work on the impact of ASA on neoplasia, showing that longer duration, and larger doses, of ASA are required to produce a protective effect against colorectal cancer. It shows that NSAIDs also reduce the risk of colorectal cancer. Like recent findings reported from the Women's Health Study,3 low doses of ASA (50 mg/d) were not effective at reducing the risk of colorectal cancer. Although this study involved only women, previous reports have shown a protective effect of ASA in men.4

Practice implications: The main practical problem with the study's findings is that most of the benefit is achieved at high doses of ASA and NSAIDs. The doses of ASA are considerably higher than those currently recommended for the prevention of cardiovascular disease and may increase the risk of gastrointestinal bleeding. The findings suggest that if 10 000 women take more than 14 tablets of ASA a week, 1 or 2 cases of colorectal cancer may be prevented over a year. However, that same dose of ASA may also cause 8 cases of bleeding severe enough to require hospital admission or blood transfusion.

Therefore, the practical application of high-dose ASA therapy is limited in day-to-day practice. Most people are unable to take ASA or NSAIDS at the high doses shown in the study to be effective in preventing colorectal cancer.

Because many of ASA's toxic effects, including gastrointestinal bleeding, are dose-dependent, further research is needed into the risk–benefit profile of ASA and other NSAIDs for chemoprevention in different risk groups.

REFERENCES

  1. 1.↵
    Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Gann PH, Manson JE, Glynn RJ, et al. Low dose aspirin and incidence of colorectal tumours in a randomized trial. J Natl Cancer Inst 1993;85: 1220-4.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Cook NR, Lee IM, Gaziano JM, et al. Low dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.Ann Intern Med 1994;121: 241-6.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 173 (10)
CMAJ
Vol. 173, Issue 10
8 Nov 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Do ASA and NSAIDs reduce the risk of colorectal cancer?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Do ASA and NSAIDs reduce the risk of colorectal cancer?
Sally Murray
CMAJ Nov 2005, 173 (10) 1159-1160; DOI: 10.1503/cmaj.051335

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Do ASA and NSAIDs reduce the risk of colorectal cancer?
Sally Murray
CMAJ Nov 2005, 173 (10) 1159-1160; DOI: 10.1503/cmaj.051335
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Azathioprine-induced severe anemia potentiated by the concurrent use of allopurinol
  • Schwannoma of the tongue
  • “Superscan” in diffusion-weighted imaging with background body suppression magnetic resonance imaging
Show more Practice

Similar Articles

Collections

  • Topics
    • Cancer: gastroenterological

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire